0 CHECKOUT

Glaucoma - Pipeline Review, H1 2015

  • ID: 3099724
  • January 2015
  • 250 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AC Immune SA
  • Amakem NV
  • Can-Fite BioPharma Ltd.
  • Gilead Sciences, Inc.
  • Lacer, S.A.
  • Ocata Therapeutics, Inc.
  • MORE

Glaucoma - Pipeline Review, H1 2015

Summary

This, ‘Glaucoma - Pipeline Review, H1 2015’, provides an overview of the Glaucoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AC Immune SA
  • Amakem NV
  • Can-Fite BioPharma Ltd.
  • Gilead Sciences, Inc.
  • Lacer, S.A.
  • Ocata Therapeutics, Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Glaucoma Overview
Therapeutics Development
Pipeline Products for Glaucoma - Overview
Pipeline Products for Glaucoma - Comparative Analysis
Glaucoma - Therapeutics under Development by Companies
Glaucoma - Therapeutics under Investigation by Universities/Institutes
Glaucoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Glaucoma - Products under Development by Companies
Glaucoma - Products under Investigation by Universities/Institutes
Glaucoma - Companies Involved in Therapeutics Development
AC Immune SA
Acadia Pharmaceuticals Inc.
Aerie Pharmaceuticals, Inc.
Alcon, Inc.
Allergan, Inc.
Altacor Ltd.
Amakem NV
Asahi Kasei Pharma Corp.
AUS Bio Limited
Bausch & Lomb Incorporated
Bionure Farma, S.L.
Can-Fite BioPharma Ltd.
Cellular Biomedicine Group, Inc.
China Grand Wuhan General Pharmaceutical Research Institute
D. Western Therapeutics Institute, Inc.
DNAVEC Corporation
Dompe Farmaceutici S.p.A.
F. Hoffmann-La Roche Ltd.
Foamix Pharmaceuticals Ltd.
Gene Signal International SA
Gilead Sciences, Inc.
Handok Inc.
High Point Pharmaceuticals, LLC
Icon Bioscience, Inc.
IMMD Inc.
Inotek Pharmaceuticals Corporation
InSite Vision Incorporated
Lacer, S.A.
Merck & Co., Inc.
Merz Pharma GmbH & Co. KgaA
Mimetogen Pharmaceuticals Inc.
NeoStem, Inc.
Neurotech Pharmaceuticals, Inc.
NicOx S.A.
Ocata Therapeutics, Inc.
Ocular Therapeutix, Inc.
Ohr Pharmaceutical Inc.
Ono Pharmaceutical Co., Ltd.
Otsuka Holdings Co., Ltd.
Oxford BioMedica plc
PharmaNova Inc.
Quark Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.
SIFI S.p.A
SK Biopharmaceuticals Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Sylentis S.A.
Teva Pharmaceutical Industries Limited
Upsher-Smith Laboratories, Inc.
Glaucoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(AR-13324 + latanoprost) - Drug Profile
(bimatoprost + brimonidine tartrate) - Drug Profile
(carteolol hydrochloride + latanoprost) - Drug Profile
(dorzolamide hydrochloride + latanoprost) - Drug Profile
(latanoprost + trabodenoson) - Drug Profile
(Prostaglandin Agonist + Beta-Blocker) - Drug Profile
(tafluprost + timolol maleate) - Drug Profile
AC-262271 - Drug Profile
ACI-260 - Drug Profile
ACN-1052 - Drug Profile
aganirsen - Drug Profile
ALT-022 - Drug Profile
AMA-0076 - Drug Profile
Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile
AP-022 - Drug Profile
APH-1104 - Drug Profile
AR-13324 - Drug Profile
AR-13533 - Drug Profile
ATS-8535 - Drug Profile
BA-1049 - Drug Profile
BA-240 - Drug Profile
bimatoprost - Drug Profile
bimatoprost SR - Drug Profile
BN-201 - Drug Profile
CF-101 - Drug Profile
CNS-102 - Drug Profile
DE-117 - Drug Profile
dorzolamide hydrochloride nanoparticle - Drug Profile
Drugs for Steroid Induced Glaucoma - Drug Profile
Drugs to Inhibit Cadherin-5 for Glaucoma - Drug Profile
Drugs to Target Bestrophin-2 for Glaucoma - Drug Profile
ENV-515 - Drug Profile
GB-201 - Drug Profile
GB-202 - Drug Profile
GB-203 - Drug Profile
GB-204 - Drug Profile
Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile
Gene Therapy for Ocular Diseases - Drug Profile
Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile
Glaucoma-GT - Drug Profile
GS-607601 - Drug Profile
H-1129 - Drug Profile
H-1129 Backup - Drug Profile
HL-5521 - Drug Profile
HPP-851 - Drug Profile
IMD-1041 - Drug Profile
KR-12 - Drug Profile
LA-8045 - Drug Profile
latanoprost - Drug Profile
latanoprost - Drug Profile
latanoprost - Drug Profile
latanoprost - Drug Profile
latanoprost SR - Drug Profile
latanoprostene bunod - Drug Profile
lomerizine - Drug Profile
Lycium Anti-Angiogenic Proteoglycan - Drug Profile
MD-920G - Drug Profile
MIMD-3 - Drug Profile
minocycline Gel - Drug Profile
Monoclonal Antibody to Activate Bves for Glaucoma - Drug Profile
MRZ-99030 - Drug Profile
NB-1111 - Drug Profile
NCX-1021 - Drug Profile
NCX-250 - Drug Profile
Neurovitas - Drug Profile
NT-501 - Drug Profile
NT-509 - Drug Profile
ONO-9054 - Drug Profile
OPA-6566 - Drug Profile
PBF-695 - Drug Profile
PRX-00933 - Drug Profile
QPI-1007 - Drug Profile
R-807 - Drug Profile
Recombinant Human Nerve Growth Factor - Drug Profile
RO-5093151 - Drug Profile
SF-103 - Drug Profile
SF-108 - Drug Profile
SF-109 - Drug Profile
SF-116 - Drug Profile
SKL-G - Drug Profile
SKS-1002 - Drug Profile
Small Molecule for Glaucoma - Drug Profile
Small Molecule for Glaucoma - Drug Profile
Small Molecule to Inhibit Rho Kinase for Glaucoma - Drug Profile
Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile
Small Molecules for CNS Disorders and Ophthalmology - Drug Profile
Small Molecules to Activate sGC for Ophthalmology - Drug Profile
Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile
Small Molecules to Antagonize TRPV4 for Glaucoma - Drug Profile
Small Molecules to Inhibit LIMK1 AND LIMK2 for Cancer and Ophthalmology - Drug Profile
SNJ-1656 - Drug Profile
SNJ-1945 - Drug Profile
Stem Cell Therapy for Glaucoma - Drug Profile
Stem Cell Therapy for Glaucoma, Cerebral Palsy and Lupus - Drug Profile
Stem Cell Therapy for Macular Degeneration and Glaucoma - Drug Profile
Stem Cell Therapy for Ophthalmic Disorders - Drug Profile
SYL-040012 - Drug Profile
Synthetic Peptide for Glaucoma - Drug Profile
tafluprost - Drug Profile
trabodenoson - Drug Profile
travoprost SR - Drug Profile
TRV-32R - Drug Profile
XY-0811QF2 - Drug Profile
XY-1303LT2 - Drug Profile
Glaucoma - Recent Pipeline Updates
Glaucoma - Dormant Projects
Glaucoma - Discontinued Products
Glaucoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Glaucoma, H1 2015
Number of Products under Development for Glaucoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2015
Glaucoma - Pipeline by AC Immune SA, H1 2015
Glaucoma - Pipeline by Acadia Pharmaceuticals Inc., H1 2015
Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H1 2015
Glaucoma - Pipeline by Alcon, Inc., H1 2015
Glaucoma - Pipeline by Allergan, Inc., H1 2015
Glaucoma - Pipeline by Altacor Ltd., H1 2015
Glaucoma - Pipeline by Amakem NV, H1 2015
Glaucoma - Pipeline by Asahi Kasei Pharma Corp., H1 2015
Glaucoma - Pipeline by AUS Bio Limited, H1 2015
Glaucoma - Pipeline by Bausch & Lomb Incorporated, H1 2015
Glaucoma - Pipeline by Bionure Farma, S.L., H1 2015
Glaucoma - Pipeline by Can-Fite BioPharma Ltd., H1 2015
Glaucoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2015
Glaucoma - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute, H1 2015
Glaucoma - Pipeline by D. Western Therapeutics Institute, Inc., H1 2015
Glaucoma - Pipeline by DNAVEC Corporation, H1 2015
Glaucoma - Pipeline by Dompe Farmaceutici S.p.A., H1 2015
Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Glaucoma - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015
Glaucoma - Pipeline by Gene Signal International SA, H1 2015
Glaucoma - Pipeline by Gilead Sciences, Inc., H1 2015
Glaucoma - Pipeline by Handok Inc., H1 2015
Glaucoma - Pipeline by High Point Pharmaceuticals, LLC, H1 2015
Glaucoma - Pipeline by Icon Bioscience, Inc., H1 2015
Glaucoma - Pipeline by IMMD Inc., H1 2015
Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H1 2015
Glaucoma - Pipeline by InSite Vision Incorporated, H1 2015
Glaucoma - Pipeline by Lacer, S.A., H1 2015
Glaucoma - Pipeline by Merck & Co., Inc., H1 2015
Glaucoma - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015
Glaucoma - Pipeline by Mimetogen Pharmaceuticals Inc., H1 2015
Glaucoma - Pipeline by NeoStem, Inc., H1 2015
Glaucoma - Pipeline by Neurotech Pharmaceuticals, Inc., H1 2015
Glaucoma - Pipeline by NicOx S.A., H1 2015
Glaucoma - Pipeline by Ocata Therapeutics, Inc., H1 2015
Glaucoma - Pipeline by Ocular Therapeutix, Inc., H1 2015
Glaucoma - Pipeline by Ohr Pharmaceutical Inc., H1 2015
Glaucoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015
Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Glaucoma - Pipeline by Oxford BioMedica plc, H1 2015
Glaucoma - Pipeline by PharmaNova Inc., H1 2015
Glaucoma - Pipeline by Quark Pharmaceuticals, Inc., H1 2015
Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015
Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2015
Glaucoma - Pipeline by SIFI S.p.A, H1 2015
Glaucoma - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015
Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015
Glaucoma - Pipeline by Sylentis S.A., H1 2015
Glaucoma - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Glaucoma - Pipeline by Upsher-Smith Laboratories, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Glaucoma Therapeutics - Recent Pipeline Updates, H1 2015
Glaucoma - Dormant Projects, H1 2015
Glaucoma - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Glaucoma, H1 2015
Number of Products under Development for Glaucoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

AC Immune SA
Acadia Pharmaceuticals Inc.
Aerie Pharmaceuticals, Inc.
Alcon, Inc.
Allergan, Inc.
Altacor Ltd.
Amakem NV
Asahi Kasei Pharma Corp.
AUS Bio Limited
Bausch & Lomb Incorporated
Bionure Farma, S.L.
Can-Fite BioPharma Ltd.
Cellular Biomedicine Group, Inc.
China Grand Wuhan General Pharmaceutical Research Institute
D. Western Therapeutics Institute, Inc.
DNAVEC Corporation
Dompe Farmaceutici S.p.A.
F. Hoffmann-La Roche Ltd.
Foamix Pharmaceuticals Ltd.
Gene Signal International SA
Gilead Sciences, Inc.
Handok Inc.
High Point Pharmaceuticals, LLC
Icon Bioscience, Inc.
IMMD Inc.
Inotek Pharmaceuticals Corporation
InSite Vision Incorporated
Lacer, S.A.
Merck & Co., Inc.
Merz Pharma GmbH & Co. KgaA
Mimetogen Pharmaceuticals Inc.
NeoStem, Inc.
Neurotech Pharmaceuticals, Inc.
NicOx S.A.
Ocata Therapeutics, Inc.
Ocular Therapeutix, Inc.
Ohr Pharmaceutical Inc.
Ono Pharmaceutical Co., Ltd.
Otsuka Holdings Co., Ltd.
Oxford BioMedica plc
PharmaNova Inc.
Quark Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.
SIFI S.p.A
SK Biopharmaceuticals Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Sylentis S.A.
Teva Pharmaceutical Industries Limited
Upsher-Smith Laboratories, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.